Aratana, Elanco Announce Global Strategic Collaboration

"This deal expands Elanco's robust companion animal portfolio, which will now give our customers and their patients a spectrum of treatments for managing osteoarthritic pain," said Jeff Simmons, president of Elanco Animal Health."At Elanco, we understand the powerful role healthy animals play in making life better. As pets become important parts of our families, the need to help them live longer, healthier, higher quality lives increases as well."

The most common type of arthritis in dogs, osteoarthritis affects up to 20 percent of the adult canine population.¹ Osteoarthritis can result when joint cartilage - the protective material that cushions and allows smooth movement in a joint – becomes thin and breaks down over time, leading to pain and inflammation in the joint. The frequent result is stiffness and a reluctance to run, jump, or even climb steps.

"Aratana understands the value of relationships with the right collaborators," said Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. "We believe that this collaboration with Elanco, a leading animal health company, is a watershed event for the emerging pet biotech sector and further validates our focus on the pet therapeutics opportunity."

Under the terms of the agreement, Aratana will receive an upfront payment of $45 million, additional payments upon achievement of certain development, regulatory and sales milestones up to $83 million, and co-promotion fees and royalty payments.

Contacts:
For Elanco inquires:
Keri McGrath Happe
Communications Manager
Elanco Animal Health
T: +1-317-370-8394
E: [email protected]

For Aratana inquires:
Craig Tooman
Aratana Therapeutics, Inc.
[email protected] 
(913) 353-1026

Important Safety Information 
GALLIPRANT^® (grapiprant tablets) is for use in dogs only. Do not use in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, or in pregnant or lactating dogs. Adverse reactions in dogs may include mild gastrointestinal effects including, vomiting, diarrhea and decreased appetite. Should not be used in dogs that have a hypersensitivity to grapiprant. If used long term, appropriate monitoring is recommended. Avoid use with COX-inhibiting NSAIDs or corticosteroids. Please see the full Prescribing Information.

ABOUT ELANCO
Elanco, a division of Eli Lilly and Company, provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. With a global presence of approximately 7,000 people and offices in more than 40 countries, Elanco anticipates, serves and supports the diverse and evolving needs of its customers--from veterinarians to food producers to all those concerned with animal health--to help them address the challenges of a diverse and changing world. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Additional information about Elanco is available at www.elanco.com, or follow us @Elanco.

ABOUT ARATANA THERAPEUTICS
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative pharmaceutical products for dogs and cats. Aratana believes that it can leverage the investment in the human pharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The Company has multiple products approved by the Food and Drug Administration's Center for Veterinary Medicine or licensed by the United States Department of Agriculture. The Company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious, unmet or underserved medical needs. Aratana believes providing innovative options to veterinarians and pet owners will help manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the collaboration between Aratana and Elanco, and reflects Lilly, Elanco's and Aratana's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that the research collaboration will yield successful results, that either company will achieve the anticipated benefits or that the results will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's and Aratana's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission, respectively. Except as required by law, Elanco and Aratana undertakes no duty to update forward-looking statements to reflect events after the date of this release.

¹ JAVMA, Vol 236, No. 1, January 1, 2010 p 59-66

Logo - http://photos.prnewswire.com/prnh/20160425/359503LOGO  
Logo - http://photos.prnewswire.com/prnh/20160425/359502LOGO

SOURCE Aratana Therapeutics, Inc.; Elanco Animal Health

Related Links

http://www.aratana.com